Total Payments
$1.4M
2024 Payments
$118,968
Companies
49
Transactions
1,994
Medicare Patients
5,766
Medicare Billing
$949,600
Payment Breakdown by Category
Other$836,371 (58.4%)
Consulting$263,165 (18.4%)
Travel$179,544 (12.5%)
Research$105,411 (7.4%)
Food & Beverage$46,602 (3.3%)
Education$425.57 (0.0%)
Gifts$8.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $824,621 | 229 | 57.6% |
| Consulting Fee | $263,165 | 68 | 18.4% |
| Travel and Lodging | $179,544 | 377 | 12.5% |
| Unspecified | $105,411 | 84 | 7.4% |
| Food and Beverage | $46,602 | 1,217 | 3.3% |
| Honoraria | $11,750 | 2 | 0.8% |
| Education | $425.57 | 16 | 0.0% |
| Gift | $8.03 | 1 | 0.0% |
Payments by Type
General
$1.3M
1,910 transactions
Research
$105,411
84 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $786,999 | 778 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $175,958 | 184 | $0 (2024) |
| Allergan, Inc. | $163,363 | 205 | $0 (2023) |
| PFIZER INC. | $63,522 | 119 | $0 (2024) |
| Ichnos Sciences Inc. | $56,982 | 15 | $0 (2022) |
| Merz Pharmaceuticals GmbH | $30,198 | 43 | $0 (2017) |
| Glenmark Pharmaceuticals Inc. | $28,157 | 58 | $0 (2019) |
| iCAD, Inc | $20,064 | 6 | $0 (2018) |
| LEO Pharma Inc. | $13,839 | 54 | $0 (2024) |
| Lilly USA, LLC | $11,483 | 68 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $118,968 | 223 | ABBVIE INC. ($110,121) |
| 2023 | $297,915 | 289 | AbbVie Inc. ($262,613) |
| 2022 | $209,827 | 281 | Allergan, Inc. ($92,220) |
| 2021 | $58,233 | 178 | AbbVie Inc. ($31,088) |
| 2020 | $131,075 | 149 | Ichnos Sciences Inc. ($45,770) |
| 2019 | $208,654 | 282 | AbbVie, Inc. ($92,262) |
| 2018 | $202,560 | 292 | AbbVie, Inc. ($85,475) |
| 2017 | $204,296 | 300 | AbbVie, Inc. ($84,973) |
All Payment Transactions
1,994 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $33.23 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $2.56 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Inflammation | ||||||
| 12/06/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Inflammation & Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $23.56 | General |
| Category: Immunology | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $10.08 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $31.42 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $9.79 | General |
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.12 | General |
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Immunology | ||||||
| 10/30/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Inflammation & Immunology | ||||||
| 10/30/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $10.04 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $7.83 | General |
| Category: Inflammation & Immunology | ||||||
| 10/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $33.52 | General |
| Category: DERMATOLOGY | ||||||
| 10/18/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $386.99 | General |
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $8.66 | General |
| Category: Immunology | ||||||
| 10/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/10/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $49.44 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GBR830-204 | Ichnos Sciences Inc. | $49,578 | 13 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $20,671 | 36 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $7,490 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $7,486 | 22 |
| ISB830-204 | Ichnos Sciences Inc. | $7,404 | 2 |
| A PHASE 4, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-122 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $7,203 | 3 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $3,000 | 1 |
| A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-122 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $2,052 | 2 |
| PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $500.00 | 2 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
| AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | Eli Lilly and Company | $2.02 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,397 | 23,011 | $496,072 | $214,104 |
| 2022 | 23 | 1,519 | 45,815 | $620,483 | $270,490 |
| 2021 | 26 | 1,494 | 21,776 | $569,439 | $250,717 |
| 2020 | 25 | 1,356 | 20,358 | $507,212 | $214,289 |
Total Patients
5,766
Total Services
110,960
Medicare Billing
$949,600
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 348 | 445 | $61,076 | $27,082 | 44.3% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 83 | 95 | $99,181 | $26,494 | 26.7% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 41 | 20,800 | $51,766 | $26,372 | 50.9% |
| 14040 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | Office | 2023 | 31 | 31 | $36,005 | $17,851 | 49.6% |
| 14041 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.1-30.0 sq cm | Office | 2023 | 20 | 23 | $32,378 | $16,208 | 50.1% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2023 | 22 | 23 | $26,988 | $13,507 | 50.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 77 | 94 | $24,516 | $12,653 | 51.6% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 25 | 29 | $18,403 | $9,638 | 52.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 93 | 97 | $17,096 | $8,274 | 48.4% |
| 14021 | Repair of wound of scalp, arms, or legs by transferring skin, 10.1-30.0 sq cm | Office | 2023 | 12 | 12 | $15,858 | $8,169 | 51.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 183 | 197 | $20,372 | $7,632 | 37.5% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 39 | 76 | $16,592 | $6,977 | 42.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 87 | 95 | $14,964 | $6,709 | 44.8% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 17 | 28 | $12,273 | $6,240 | 50.8% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 14 | 16 | $15,684 | $4,363 | 27.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 54 | 54 | $9,164 | $4,270 | 46.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 143 | 775 | $8,060 | $3,997 | 49.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 46 | 50 | $4,304 | $2,175 | 50.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 23 | $4,455 | $2,152 | 48.3% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 15 | 15 | $3,079 | $1,399 | 45.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $2,145 | $1,049 | 48.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 15 | 22 | $1,713 | $895.41 | 52.3% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2022 | 79 | 43,400 | $106,060 | $54,061 | 51.0% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 94 | 117 | $121,744 | $32,645 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 328 | 406 | $50,160 | $25,003 | 49.8% |
About Dr. William Werschler, MD
Dr. William Werschler, MD is a Dermatology healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023119682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Werschler, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $118,968 received in 2024. These payments were reported across 1,994 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($824,621).
As a Medicare-enrolled provider, Werschler has provided services to 5,766 Medicare beneficiaries, totaling 110,960 services with total Medicare billing of $949,600. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties MOHS-Micrographic Surgery, Procedural Dermatology
- Location Spokane, WA
- Active Since 09/26/2006
- Last Updated 03/11/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1023119682
Products in Payments
- SKYRIZI (Biological) $179,070
- Humira (Biological) $151,290
- BOTOX (Biological) $141,119
- RINVOQ (Biological) $117,607
- EUCRISA (Drug) $62,022
- XEOMIN (Biological) $56,572
- GBR830-204 (Drug) $45,770
- Skyrizi (Biological) $40,776
- Xeomin (Biological) $25,695
- Axxent Controller (Device) $20,064
- HUMIRA (Biological) $10,510
- QBREXZA (Drug) $9,593
- TALTZ (Drug) $8,789
- Sotyktu (Drug) $6,534
- Otezla (Drug) $6,035
- ARAZLO (Drug) $5,898
- BOTOX COSMETIC (Biological) $4,840
- COSENTYX (Biological) $3,998
- ENSTILAR (Drug) $2,847
- PICATO (Drug) $2,362
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Spokane
Katherine Reed, M.d, M.D
Dermatology — Payments: $7,961
Dermatology $7,961
Dr. Joyce Park, Md, MD
Dermatology — Payments: $7,717
Dermatology $7,717
Dr. John Nia, M.d, M.D
Dermatology — Payments: $7,335
Dermatology $7,335
Mr. William Wray, M.d, M.D
Dermatology — Payments: $6,823
Dermatology $6,823
Richard Herdener, M.d, M.D
Dermatology — Payments: $5,894
Dermatology $5,894
Brittany Urso
Dermatology — Payments: $3,589
Dermatology $3,589